Bicyclo<2.2.2>octen-(2)-2-carbaldehyd | 16317-25-2

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机氧化物
• 英文名称: Bicyclo<2.2.2>octen-(2)-2-carbaldehyd
• 英文别名: Bicyclo[2.2.2]oct-2-ene-2-carbaldehyde
• CAS: 16317-25-2
• 化学式: C₉H₁₂O
• 分子量: 136.194
• InChiKey: VKFHEAFOHXQVFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] OXAZOLE COMPOUNDS AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS<br/>[FR] COMPOSES D'OXAZOLE CONVENANT COMME AGONISTES OU ANTAGONISTES DE LA PROSTAGLANDINE E2
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2000018744A1

  公开（公告）日：2000-04-06

  Oxazole compounds of formula (I), wherein R1 is aryl which may be substituted with halogen(s), R2 is aryl which may be substituted with halogen(s), X is single bond, (a) or SO¿2?, R?3 and R4¿ are independently hydrogen or suitable substituent, (wherein X is (a), neither R?3 nor R4¿ is hydrogen), R?3 and R4¿ may be linked together to form (b), (b) is N-containing heterocyclic group which may be substituted with one or more suitable substituent(s), R5 is hydrogen, etc., A1 is lower alkylene or single bond, (c) is cyclo(C¿3?-C9)alkane or cyclo(C5-C9)alkene, or a pro-drug thereof, or a pharmaceutically acceptable salt thereof, which are useful as medicament.

  式(I)的噁唑化合物，其中R1是芳基，可以用卤素取代，R2是芳基，可以用卤素取代，X是单键，（a）或SO¿2？，R?3和R4¿分别是氢或合适的取代基，（其中X是（a），R?3和R4¿均不是氢），R?3和R4¿可以连接在一起形成（b），（b）是含氮杂环基团，可以用一种或多种适当的取代基取代，R5是氢等，A1是较低的烷基或单键，（c）是环（C¿3?-C9）烷基或环（C5-C9）烯烃，或其前药或其药学上可接受的盐，可用作药物。
• Dihydropyridine derivatives and their production, formulation and use as pharmaceuticals
  申请人：FISONS plc

  公开号：EP0174071A2

  公开（公告）日：1986-03-12

  There are described compounds of formula I, in which R2 and R3, which may be the same or different, each represent alkyl C1 to 6 or cycloalkyl C3 to 8, R7 and R8, which may be the same or different, each represent alkyl C1 to 6 optionally substituted by halogen, and X, Y and Z, which may be the same or different, are each hydrogen, halogen, nitro or alkyl C1 to 6 optionally substituted by halogen, or Z is as defined above and X and Y, together with the carbon atoms to which they are attached, form a C5 to 8 carbocyclic ring, other than a benzene ring, provided that when R2, R3, R7 and R8 are all methyl and X and Z are hydrogen; or when R2 and R3 are both ethyl, R7 and R8 are both methyl and X and Z are hydrogen; then Y is other I than methyl. There are also described methods for making the compounds and their formulation and use as pharmaceuticals, e.g. for the treatment of cardiovascular conditions.

  所述化合物为式 I、 其中 R2 和 R3 可以相同或不同，各自代表 C1-6 烷基或 C3-8 环烷基、 R7 和 R8（可以相同或不同）各自代表 C1-6 烷基，可选被卤素取代，以及 X、Y 和 Z（可以相同或不同）各自为氢、卤素、硝基或任选被卤素取代的 C1 至 6 烷基，或 Z 如上文所定义，且 X 和 Y 与它们所连接的碳原子一起形成 C5 至 8 碳环（苯环除外）、 条件是当 R2、R3、R7 和 R8 均为甲基，且 X 和 Z 均为氢时；或当 R2 和 R3 均为乙基，R7 和 R8 均为甲基，且 X 和 Z 均为氢时；则 Y 为甲基以外的其他 I。 此外，还介绍了这些化合物的制造方法及其配制和用作药物的方法，例如用于治疗心血管疾病。
• OXAZOLE COMPOUNDS AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1115712A1

  公开（公告）日：2001-07-18
• Combination of Prostaglandin E2 Receptor Antagonists and Renin-Angiotensin System Inhibitors for Treating Renal Diseases
  申请人：Sogabe Hajime

  公开号：US20080275095A1

  公开（公告）日：2008-11-06

  This invention relates to methods for treating renal diseases by using combination of prostaglandin E2 receptor antagonist and renin-angiotensin system inhibitor and pharmaceutical compositions for treating renal diseases comprising prostaglandin E2 receptor antagonist and renin-angiotensin system inhibitor.